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Evaluation of the Clonal Origin of Multiple Primary
Melanomas Using Molecular Profiling
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Klaus J. Busam2, Achim A. Jungbluth3, Richard A. Scolyer4, John F. Thompson4, Bruce K. Armstrong5,
Marianne Berwick6, Nancy E. Thomas7 and Colin B. Begg1
Numerous investigations have been conducted using molecular profiling to evaluate the possible clonal origin
of second malignancies in various cancer types. However, to date no study assessing clonality of multiple
primaries has been conducted in melanoma. In this investigation using patients treated at a specialist melanoma
treatment center, we compared the somatic mutational profiles of pairs of melanomas designated as
independent on the basis of thorough assessment of their clinical and pathologic characteristics. We used a set
of highly polymorphic genetic markers selected on the basis of their chromosomal positions and the
frequencies of reported allelic losses at these genetic loci. Our statistical testing strategy showed no significant
evidence of clonal origin of the two primaries in 17 of the 19 patients examined. The results suggest that most
second melanomas designated as independent primary tumors on the basis of their clinicopathologic features
are indeed independent occurrences of the disease, supporting the validity of the criteria used by experienced
pathologists in distinguishing new primaries from metastases.
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INTRODUCTION
In recent years, many investigative studies using new
molecular technologies have sought to distinguish indepen-
dent primary cancers from metastases in a more definitive
manner than is possible by routine assessment of clinical and
pathologic features. These have been conducted in various
organ systems using molecular profiling of cells from pairs of
tumors from individual patients, and a large literature of these
studies has been developed, most prominently in the area of
head and neck cancer (Ha and Califano, 2003) and bladder
cancer (Hafner et al., 2002), the two sites in which second
malignancies are common. Typically, this has involved the
examination of the tumors for somatic mutations in genes that
are frequently altered in cancers of the type under investiga-
tion, by examining microsatellite instability or loss of
heterozygosity (LOH) at mutational hot spots in which LOH
occurs frequently. The similarities of the genetic events in
both tumors are then examined to determine whether they
appear to be closely matched. If so, the tumors are
considered to be ‘‘clonal’’, that is deriving from a single cell
that experienced the pivotal mutations before seeding both
tumors.
Molecular studies of clonality have been prominent in
understanding the development of smoking-related aerodi-
gestive cancers. The concept of field cancerization postulates
distinct tumors developing independently due to a common,
regional exposure to the carcinogen (Slaughter et al., 1953).
Molecular studies, however, have demonstrated that fre-
quently these subsequent primaries are in fact clonally
related (Worsham et al., 1995; Bedi et al., 1996; Scholes
et al., 1998). A contrasting picture emerges from studies of
contralateral cancer of the breast and lung. Authors of these
studies have generally reached the conclusion that the tumors
are typically independent for contralateral breast cancers
(Kollias et al., 2000; Janschek et al., 2001; Stenmark-
Askmalm et al., 2001; Imyanitov et al., 2002; Tse et al.,
2003; Chunder et al., 2004; Regitnig et al., 2004; Schlechter
et al., 2004), although corresponding studies of new
ipsilateral breast cancers indicate that these are predomi-
nately of clonal origin (Goldstein et al., 2005a, b). Studies in
lung cancer have been conducted using microsatellite
markers to distinguish microsatellite instability (Leong et al.,
1998; Huang et al., 2001; Shin et al., 2001; Dacic et al.,
2005; Geurts et al., 2005), and several have tested mutations
in TP53 and/or K-ras (Sozzi et al., 1995; Lau et al., 1997;
Hiroshima et al., 1998; Holst et al., 1998; Matsuzoe et al.,
1999; Shimizu et al., 2000; Shin et al., 2001; van Rens et al.,
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2002; Murase et al., 2003). These studies have evaluated
clonality in a range of clinical settings, including the
comparison of synchronous or metachronous multiple
primaries, comparisons of primaries with metastatic tumors,
and comparison of head and neck primaries with solitary
lung nodules that may or may not be metastases. The results
of these studies are mixed, but similarly to breast cancer the
evidence appears to suggest that contralateral lung tumors are
predominantly of independent origin.
Our study was stimulated by the importance of this issue
for interpreting findings from epidemiologic studies of
melanoma. Melanoma is a relevant model for the study of
clonality because the reported frequency of second primary
melanoma is high: melanoma patients experience a rate of
occurrence of melanoma about seven to eight times greater
than the age-matched general population (Begg, 2001).
Furthermore, it is not uncommon for individual patients to
develop several primary melanomas. These patients provide a
rich potential resource for cancer epidemiologic research
(Neugut et al., 1999). Patients with second primaries are
increasingly used in epidemiologic case–control studies (see
for example, Berwick et al., 2006; Kanetsky et al., 2006;
Millikan et al., 2006; Orlow et al., 2007; Concannon et al.,
2008). Risk factors occur with greater frequency in these
patients than in patients with a single malignancy or in
population controls. As a consequence, epidemiologic
studies using second primaries can possess greatly enhanced
statistical power compared with conventional studies, espe-
cially for the study of rare, highly penetrant genetic risk
factors (Begg and Berwick, 1997). These types of studies rely
on the assumption that individuals recruited on the basis of
the diagnosis of a second primary tumor have truly
experienced a cancer diagnosis twice (Begg et al., 2006).
However, it is plausible that a significant subset of these
second- and higher order primaries involve clonal recur-
rences of the initial primary tumor, misdiagnosed as
independent second primaries.
There are several criteria for classifying a new melanoma
as an independent primary. The strongest evidence in favor of
a primary tumor is the presence of an associated precursor
lesion (melanocytic nevus or in situ melanoma). Additional
criteria to differentiate metastatic and primary lesions include
location, grouping, invasion of lymphatic capillaries, and the
presence of a brisk inflammatory cell infiltrate, although
some of these characteristics may be shared by both
primaries and metastatic melanomas (Heenan and Clay,
1991; Bengoechea-Beeby et al., 1993). For pathologists
familiar with the spectrum of pathologic features of melano-
cytic tumors it is usually not difficult to establish a pathologic
diagnosis of primary cutaneous melanoma, particularly if the
diagnosis is made in the context of an appropriate clinical
history. However, it can be difficult or even impossible to
determine whether a melanoma is a primary tumor or a
metastasis on the basis of histologic characteristics alone
(Guerriere-Kovach et al., 2004). This is particularly the case
for melanomas involving the dermis devoid of an in situ
component in the overlying epidermis or other associated
precursor lesions. Such tumors may be diagnosed incorrectly
as metastatic melanoma on pathologic assessment. Conver-
sely, some metastatic melanomas can show prominent
epidermotropism, mimicking a primary tumor (Abernethy
et al., 1994; White and Hitchcock, 1998; Swetter et al.,
2004). In some instances, the clinical features may be the
only clues to the recognition that the tumor is, in fact, a
metastasis.
In the light of these issues it is surprising that the clonal
relationship between first and second primary melanomas
has not been investigated earlier using molecular techniques.
Clonality has been examined for ‘‘in-transit’’ melanoma
metastases by investigating LOH at eight candidate loci in the
primary tumors and the lymphatic metastases, demonstrating
a close concordance of the genetic fingerprints of lesions
derived from the same patient (Nakayama et al., 2001). A
more recent study compared X-chromosome inactivation
and LOH in five loci between primary melanomas and
their corresponding metastases, and the results revealed
that the majority of melanoma metastases share a common
clonal origin with the matched primary tumor (Katona et al.,
2007). Furthermore, a group of investigators led by Bastian
et al. (1998, 1999, 2000, 2003) has conducted a series of
studies examining copy number changes in melanomas
and benign nevi using array comparative genomic hybridiza-
tion techniques (Curtin et al., 2005). They showed that the
benign nevi exhibited very few copy number abnormalities
relative to the malignant tumors, confirming the potential
value of molecular profiling as a diagnostic tool in
differentiating benign from malignant melanocytic
tumors. However, to our knowledge, no studies have been
conducted that seek to challenge the validity of the diagnosis
of new primary melanomas as independent occurrences of
cancer.
Determining whether a melanoma is a primary or a
metastasis is of critical clinical importance. In contrast
to a new primary, metastatic disease is rarely curable.
Furthermore, primary melanomas and melanoma
metastases are managed clinically in quite different ways.
Also, as noted above, the distinction is important for
the validity of epidemiologic studies of multiple primary
cancers.
RESULTS
We compared the mutational profiles of pairs of presump-
tively independent primary melanomas for each of a series of
19 patients who had been treated at the Sydney Melanoma
Unit, Royal Prince Alfred Hospital in Sydney, Australia. These
comparisons were on the basis of 26 highly polymorphic
markers (Table 1). LOH is represented in the table by black
triangular symbols, with the direction of the symbol
distinguishing losses on the short versus long allele. Thus,
concordant black triangles indicate losses of the same allele
at the same locus and represent potentially clonal mutations,
though clearly such concordances could occur indepen-
dently on the two tumors by chance. Likewise, independent
mutations could occur in either tumor even if the tumors
shared a clonal origin. To assess the evidence favoring
clonality, we used a statistical test that determines whether
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the number of concordant mutations exceeds the number
expected on the basis of chance.
For most of the cases, the patterns of LOH appear to be
random. The results of the statistical tests displayed at the
bottom of the table indicate that only 2 of the 19 cases have
statistically significant evidence of clonal relatedness,
P¼0.01 for case no. 34 and P¼0.04 for case no. 30. As
we used a statistical test with a significance level of 5% we
expect one ‘‘significant’’ finding when we perform about 20
independent tests. Case no. 34 has relatively few mutations,
three on the first tumor (T1) and two in the second tumor (T2),
with the two common mutations occurring on the same
allele. Case no. 30 showed genetic alterations in both tumors
for seven of the markers, with six of these seven occurring on
the same allele. Interestingly, case no. 34 involved two
synchronously occurring melanomas, both on the trunk, and
both superficial spreading melanomas (clinical details of all
cases are provided in Table 3). In contrast, case no. 30
involved tumors that occurred 2.4 years apart in distinct
anatomic locations and with different cell types. These data
suggest that most of these tumor pairs are independent,
confirming the pathologic diagnoses, though we cannot rule
out the possibility that one or two are clonal.
To verify that our testing procedure has the potential to
detect tumor pairs whose origin is clonal we also examined
13 metastatic tumors from five patients (one patient had four
metastases and another had three), obtained from archival
material from Memorial Sloan-Kettering Cancer Center in
New York. As shown in Table 2, 10 of the 12 comparisons of
these definitively clonal pairings demonstrated statistically
significant evidence of clonal relatedness (sensitivity¼ 83%),
with eight of the pairings producing strongly significant
(Po0.01) findings.
DISCUSSION
Although a number of studies of the possible clonal origin
of double malignancies have been conducted to date,
none to our knowledge have involved double primary
melanomas. This absence may be due to the fact that
most dermatopathologists do not perceive the misdiagnosis
of a metastasis as a second primary as a likely occurrence or
as a diagnostic problem. However, the high incidence of
reported multiple primaries in this disease could be due in
part to the misdiagnosis of metastases as independent
primaries. Our study was constructed to provide preliminary
evidence on this issue. The results would appear to support
the conclusion that most second primary melanomas
diagnosed on the basis of their clinical and pathologic
characteristics are indeed independent occurrences of the
disease.
It is of interest to examine more closely the two cases that
showed patterns suggestive of clonal relatedness. Case no. 30
Table 1. Mutational patterns observed in patients with multiple primary melanomas
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exhibited concordant LOH at six separate genetic loci, yet the
tumors have different cell types, occurred 2.4 years apart, and
were located in distant anatomic sites. A re-inspection of the
pathological characteristics indicated that both tumors had
significant epidermal components extending beyond bulky
dermal components. Case no. 34 had only two concordant
mutations, but the overall patterns were very similar, that is
most of the loci exhibited no mutations on either tumor. The
two tumors were synchronous, with the same cell type in the
same general anatomic site, the chest, although the tumors
were in the left and right portions of the chest, and well apart.
Re-examination of the pathology in recut sections showed
that the two tumors were mostly epidermal, and thus
appeared pathologically to be independent primaries. As
we expect one false-positive finding for every 20 statistical
tests performed at the 5% significance level, the observation
of only two significant results in this set of 19 is broadly
consistent with the conclusion that few, if any, of these
melanoma pairs, and very few in general, are of clonal origin.
Our study has technical, epidemiological, and statistical
limitations. We obtained specimens from both primaries for
19 cases, but these cases were selected based on the
availability of sufficient tissue samples. This opportunistic
selection of cases, and the small sample size, limits our ability
to estimate accurately the proportion of cases that may be
misdiagnosed. Furthermore, the cases were obtained from a
specialized melanoma treatment center where the pathologic
reviews were accomplished by dermatopathologists specia-
lizing in melanoma, and where full clinical histories were
also available. All such information is rarely available to
either clinicians or pathologists at the time of initial diagnosis
in routine clinical practice and hence misdiagnosis of a
metastasis as a primary may be somewhat more common in
everyday clinical practice, particularly outside of specialist
centers. Nonetheless, most patients with a second skin
melanoma designated as a second primary have clinical
courses consistent with a new primary and more favorable
than would be expected for stage IV melanomas. For a subset
of markers we encountered amplification failures. This could
be the result of primers being unable to anneal to their
specific sequences due to homozygous deletions or duplica-
tions, but more likely the high rate of failures encountered
for D2S131, D2S2291, D6S275, D6S457, D10S185, and
D13S153 was due to the suboptimal quality of the DNA.
Table 1. Continued
LOH, loss of heterozygosity.
m LOH (short allele); . LOH (long allele); I informative/no change; – non-informative.
We used the term LOH for simplicity, but gain of the contralateral allele has been observed for some markers by us and others (Bastian et al., 1998; White
and Hitchcock, 1998; Curtin et al., 2005).
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Melanoma is a disease that is frequently characterized by
small tumors. We had hoped as part of this study to conduct
array comparative genomic hybridization on all pairs of samples
as an alternative genomic approach to profiling the tumors.
However, sufficient DNA of high molecular weight suitable for
array comparative genomic hybridization for both tumors in the
pair was available only for four cases (data not shown). In
general, for a technology of this nature to be applicable in a
clinical diagnostic setting, we would need a minimum of 0.6mg
of high-molecular-weight DNA from each tumor and counter-
part normal sample if extracted from fresh frozen tissue, or
1.5mg of DNA extracted from formalin-fixed, paraffin-em-
bedded tissue. Such quantities will typically not be available
from both tumors. With a PCR-based method such as the one
presented here, one would require no more than 0.5mg of DNA
if testing a relatively high number of microsatellite repeats, and
approximately 0.2mg when working with fresh-frozen tissue.
We employed a statistical test that was designed specifi-
cally for the purpose of detecting clonal relatedness (Begg
et al., 2007). This test is based on the simplifying assumptions
that the mutations at different loci are independent, that the
probabilities of mutations are similar for each locus, and that
each allele is equally likely to experience a mutation. Each of
these assumptions is clearly approximate. Validation studies
show that the test is robust to modest departures from the
latter two assumptions (Begg et al., 2007). In fact, in our
presumptively independent cases, 66% of the losses that
occurred in both members of the tumor pair occurred on the
same allele. This modest preponderance of concordances
could be the result of clonality in some of the pairs (such as
case nos. 30 and 34), but it may also be explained by the
possibility that allelic changes do not occur with equal
probability for the alleles at specific genetic loci, especially if
located within or nearby a gene involved in the development
of the tumor. If this is true, then we expect to see a modest
correlation in mutational profiles even for independent
tumors. The statistical power of the test is, of course,
dependent on the number of independent genetic markers
evaluated. In practice, one could increase power by
examining more loci for allelic gains and losses and by
testing for the presence of common point mutations such as
the V600E variant on the BRAF gene.
Table 2. Mutational patterns observed in controls with metastases
(1) P=0.01 (T1 vs T2); P=0.02 (T1 vs T3); P=0.50 (T2 vs T3).
(2) Po0.01 (T1 vs T2); Po0.01 (T1 vs T3); Po0.01 (T1 vs T4); Po0.01 (T2 vs T3); Po0.01 (T2 vs T4); Po0.01 (T3 vs T4).
1976 Journal of Investigative Dermatology (2009), Volume 129
I Orlow et al.
Molecular Profiling of Melanomas
In summary, our study provides evidence that most
melanomas that are classified as independent second
primaries on the basis of comprehensive clinicopathologic
analysis in a specialist melanoma treatment center are indeed
independent occurrences of melanoma. In clinical use, this
technology could, on present evidence, be a supplement to
but not a replacement for detailed clinical and pathologic
evaluation of the lesions.
MATERIALS AND METHODS
Case selection
Archival specimens of sufficient quality for analysis were obtained
from two independent primary melanomas for each of a series of 19
patients who had been treated at the Sydney Melanoma Unit, Royal
Prince Alfred Hospital in Sydney, Australia. These cases were
selected on the basis of the availability of specimens from both
tumors with dimensions (based on diameter and thickness) that were
likely to provide sufficient DNA for analysis. Clinical and pathologic
details are reported in Table 3. In 13 patients, the tumor pairs
occurred in the same general anatomic region and in 16 pairs the
tumors were of the same histologic type. In 10 of these patients, the
lesions mapped both to the same anatomic region and had the same
histologic subtype. For comparison, we also utilized 13 ‘‘known’’
metastatic lesions in five patients with melanoma available as
archived material at the Memorial Sloan-Kettering Cancer Center in
New York. One patient had four synchronous tumors to the leg
(control no. 2, Table 2), whereas another patient had three related
tumors (control no. 1). The study was approved by the Institutional
Review Boards at the Royal Prince Alfred Hospital and Memorial
Sloan-Kettering Cancer Center. The study was conducted according
to the Declaration of Helsinki Principles.
Marker selection
We chose 26 highly polymorphic genetic markers; these were
selected on the basis of their chromosomal positions and their
reported or expected allelic loss (Table 4) (Thompson et al., 1995;
Nakayama et al., 2001; Shirasaki et al., 2001; Massi et al., 2002;
Pollock et al., 2003; Uribe et al., 2005). Eleven of these markers map
to eight different chromosomes and have earlier shown a high
incidence of LOH or microsatellite instability (430%) either in
primary or metastatic melanomas (35,46–48): D1S214 (1p36.3),
D2S2182 (2p16), D2S2291 (2p16), D6S275 (6q15–q16), D6S457
(6q21–q23.2), D9S304 (9p21), D9S157 (9p23–p22), D10S212
(10q26.12–13), D11S2000 (11q22–q23), D13S153 (13q14),
D17S786 (17p13), and D17S1322 (17q21). The heterozygosity of
these markers ranged from 20 to 62% in published studies
(Bengoechea-Beeby et al., 1993; Thompson et al., 1995; Shirasaki
et al., 2001; Pollock et al., 2003) and from 61 to 92% according to
the Centre d0Etude du Polymorphisme Humain database (version
v2.1 last accessed on 8 April 2008). The following six markers with
heterozygosities between 69 and 87% (Centre d0Etude du Poly-
morphisme Humain) have not been tested earlier in melanomas but
were selected because they map to chromosomal arms found by
Curtin et al (2005) to be altered: D6S1043 (6q16), D7S1824 (7q34),
D8S1104 (8p11), D10S676 (10q22), D11S1998 (11q23), and a
pentanucleotide repeat within the TP53 gene (17p13). An additional
set of five markers on three different chromosomes showed 19–23%
LOH in melanoma cases as reported by Uribe et al. (2005): D10S185
(10q23.3), D2S139 (2p12), D2S131 (2p22–25), and D2S206
(2q33–37). Finally, four more markers were selected that were at
known or suspected oncogene or tumor suppressor gene sites. These
markers are D4S1543 on 4q13 (c-Kit maps to 4q11–12), D1S2882
and D1S2766, which map to the smallest overlapping deletion
(SRO1) suspected to harbor a new melanoma tumor suppressor gene
(Walker et al., 2004), and D3S1293 on 3p22, which maps near
TGFBR2 (Nakayama et al., 2001), with heterozygosities between 67
and 74% (Centre d0Etude du Polymorphisme Humain).
Sample preparation and DNA extraction
DNA was extracted from the tumor area contained in 20–30 5-mm-
thick formalin-fixed paraffin-embedded tissue sections placed on
uncharged glass slides. A hematoxylin–eosin-stained slide was used
to confirm the presence of tumor and to differentiate between
tumor and normal adjacent cells. These areas were then isolated
and scraped into separate Eppendorf tubes with sterile scalpels.
Tissues were deparaffinized with xylene and DNA extracted with
the QIAamp Micro Kit (Qiagen Inc., Valencia, CA) following
the manufacturer’s recommendations. The DNA quantity and
quality were determined by measuring the A260, A280, and
A230 with a NanoDrop ND1000 spectrophotometer (Nanodrop,
Wilmington, DE).
Table 3. Clinical and histologic characteristics of
multiple melanomas
First primary Second primary
Case
ID Thickness Site Histology Thickness Site Histology Interval1
12 2.1mm H/N SSM 1.3mm H/N SSM 9.5 years
13 4.6mm Trunk SSM 0.5mm Trunk SSM Synch
14 0.9mm Arm SSM 1.7mm H/N SSM 1.2 years
15 1.2mm Trunk SSM 2.7mm Trunk NM 1.3 years
16 1.2mm Arm SSM 0.8mm Trunk SSM 7.1 years
19 1.7mm H/N LMM 2.5mm H/N NM 6.2 years
20 1.2mm Trunk SSM 1.8mm H/N SSM 0.8 years
22 1.7mm Trunk SSM 0.9mm Trunk SSM 0.3 years
23 1.3mm Leg SSM 1.9mm Leg SSM 6.4 years
25 0.6mm Arm SSM 0.9mm Arm SSM 0.6 years
26 2.2mm Trunk SSM 0.4mm Trunk SSM Synch
27 0.5mm Trunk SSM 1.0mm Trunk NM 4.1 years
28 0.6mm Trunk SSM 1.8mm Trunk SSM 4.2 years
29 0.6mm Trunk SSM 1.1mm Trunk SSM Synch
30 5.7mm Trunk NM 8.0mm Leg LMM 2.4 years
31 0.7mm Leg SSM 1.0mm Arm SSM Synch
32 1.2mm Trunk SSM 1.7mm Trunk SSM 1.0 years
33 0.5mm Trunk SSM 0.5mm Leg SSM Synch
34 0.7mm Trunk SSM 0.5mm Trunk SSM Synch
H/N, head and neck; LMM, lentigo malignant melanoma; NM, nodular
melanoma; SSM, superficial spreading melanoma.
1Time (years) between diagnoses; Synch, synchronous dates of diagnosis.
www.jidonline.org 1977
I Orlow et al.
Molecular Profiling of Melanomas
PCR and fragment-size analysis
Analyses of microsatellites were performed by PCR using primers
flanking the repetitive sequence, coupled with fragment-size
analysis using a fluorescent label. During assay design, all primer
pairs were checked with the Basic Local Alignment Search Tool
(Blast, NCBI) to ensure specificity. Specific fragments were amplified
in a reaction mix containing 10–15 ng of DNA, 0.5 mM each of the
specific forward and reverse primers, 300mM of dNTP, 0.05U ml1 of
DNA polymerase, and AmpliTaq Buffer II containing 1.5mM of
MgCl2 (Applied Biosystems, Foster City, CA). Specific primer
sequences amplified products of 103–247 bp and are listed, together
with the cycling conditions, in Table 5. After amplification, the
Table 4. Microsatellite markers for the study of melanoma clonality
Chromo-
some Location Marker
Genes
nearby Het. LOH (%)1 Het.2 Primer forward (5030)3 Primer reverse (5030)3
1 p36.3 D1S214 BW2,
BMND3,
SCCD
19/79 (24%)(b) 6/19 (32%) 74% CCGAATGACAAGGTGAGACT AATGTTGTTTCCAAAGTGGC
p22 D1S2766 CYR61 Not clear(a) Not clear 74% CTCAGCCTAGTGCAGCC GCTTAAACCCATGATTGGTAT
p31 D1S2882 BCL10 Not clear(a) Not clear 74% AATGAAAATTGTAGTA
CCTGTTTCG
CTTGCTAAGGATGATAGCCTC
2 p22–p25 D2S131 ITGB1BP1 21/29 (72%)(c) 4/21 (19%) 86% TTTACTGCTGAGACAACCCA GTATAGGAGCCACACCCCTG
p16 D2S2182 MSH2 Not clear(d) 60% MSI 75% GCTCGAAAAATGATTTGATCC GGCTAAGCCTAGATGCTTGA
p16 D2S2291 MSH2 Not clear(d) 60% MSI 75% TGTCAACAGTGGCTAATCATC TTAGAAATATGGCTGCCAGG
p12 D2S139 DFNA43 21/29 (72%)(c) 4/21 (19%) 83% AGCTCAAAGCAAATGCATGC AAATTGCGAAACTGTGGCTT
q33–q37 D2S206 PARK11 9/29 (31%)(c) 2/9 (22%) 86% TTAAAAATTAAGTAGGC
TTTTGGTT
GTCCTCATGTGTTTATGCTGT
3 p22 D3S1293 TGFBR2 21/25 (84%)(b) 2/21 (10%) 74% ACTCACAGAGCCTTCACA CATGGAAATAGAACAGGGT
4 q13 D4S1543 KIT,
SULT1E1
67% TTCCAGCAATAGGGATGGAGTC CGAAAGTAGTTAATATGG
CTTCCGA
6 q15–q16 D6S275 KiSS1
regulators
Not clear(e) (52%) 86% TAATTTCACATACAGGCCCT AATGAACACGCTCTAAGGAT
q21–q23.2 D6S457 TCF21 Not clear(e) (52%) 82% ATTGGCAATAGTTACGAATTA GGCATTTGTGGAGTGG
q16 D6S1043 RRAGD,
CASP8AP2
83% CAAGGATGGGTGGATCAATA TTGTATGAGCCACTTCCCAT
7 q34 D7S1824 ADCK2,
BRAF
87% GTTTGATTCAGTCAGTGG TGGGATAGAACAGAATAG
8 p11 D8S1104 PLAT,
ADRB3
78% TCAGCTATGAGAAAAGTTGAATG GACCCTTGTTTGTGTACGGT
9 p21 D9S304 CDKN2A 17/79 (22%)(b) 8/17 (47%) 86% GTGCACCTCTACACCCAGAC TGTGCCCACACACATCTATC
p22–p23 D9S157 PTCH,
SH3GL2
16/79 (20%)(b) 9/16 (56%) 87% AGCAAGGCAAGCCACATTTC TGGGGATGCCCAGATAA
CTATATC
10 q23.3 D10S185 PTEN 13/29 (45%)(c) 3/13 (23%) 82% TCCTATGCTTTCATTTGCCA CAAGACACACGATGTGCCAG
q26.12–13 D10S212 MKI67 17/79 (22%)(b) 6/17 (35%) 66% GAAGTAAAGCAAGTTCT
ATCCACG
TCTGTGTACGTTGAAAATCCC
q22 D10S676 LRRC20 90% GAGAACAGACCCCCAAATCT ATTTCAGTTTTACTATGTGCATGC
11 q22–q23 D11S2000 ATM 23/79 (29%)(b) 9/23 (39%) 92% AGTAGAGAACAAAACAC
TGTGGC
TTTGAAGATCTGTGAAATGTGC
q23 D11S1998 SCN2B 23/27 (85%)(f) 20/23 (87%) 69% AGCCATCAACTAGCTTTCCC GGGAGGCACCAACAGATG
13 q14 RBi2 /
D13S153
RB1 15/29 (52%)(c) 6/15 (40%) 64% AGCATTGTTTCATGTTGGTG CAGCAGTGAAGGTCTAAGCC
17 p13 D17S786 TP53 18/29 (62%)(c) 5/18 (28%) 82% TACAGGGATAGGTAGCCGAG GGATTTGGGCTCTTTTGTAA
q21 D17S1322 BRCA1 12/29 (41%)(c) 4/12 (33%) 67% CTAGCCTGGGCAACAAACGA GCAGGAAGCAGGAATGGAAC
p13 TP53 TP53 72% GAATCCGGGAGGAGGTTG AACAGCTCCTTTAATGGCAG
Het., Heterozygosity; LOH, loss of heterozygosity as reported by others: (a) Walker et al. (2004); (b) Nakayama et al. (2001); (c) Uribe et al. (2005); (d) Massi
et al. (2002); (e) Shirasaki et al. (2001); (f) Herbst et al. (2000).
1LOH/informative cases (%).
2Heterozygosity as reported by the Centre d’Etude du Polymorphisme Humain (CEPH), except for marker D17S1322, reported by the GDB.
3Primer sequences obtained from NCBI-UniSTS (STS, sequence-tagged site), Primer3 online tool (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi),
and Cawkwell et al. (1994).
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products were loaded onto 2.5% agarose gels stained with ethidium
bromide and examined after electrophoresis. The quantity of PCR
product obtained was assessed by comparing the band intensities to
a mass marker (Invitrogen, Carlsbad, CA). PCR products were diluted
to 1–3 ng ml1 and then analyzed by capillary electrophoresis on the
ABI 3730xl DNA sequencer (Applied Biosystems) in the presence of
a GS500LIZ size standard (Applied Biosystems) and by use of the
GeneScan ver3.0 software (Applied Biosystems) to determine
product length. The electropherograms were analyzed with Peak
Scanner v1.0 software (Applied Biosystems) and the ABI PRISM
GeneMapper TM Software version 3.0. Samples were considered
informative when two clear allelic peaks were present in the
electropherograms of the normal DNA (heterozygous sample), and
not informative when only one peak was present (homozygous
sample). For the informative sets, the ratios of allele 1 and allele 2
signals were compared in normal (N) and tumor tissue (T) [(Nallele1/
Nallele2): (Tallele1/Tallele2)]. This ratio should be close to 1 when no
allelic loss has occurred. We note that as the PCR-based
microsatellite analysis consists of examination of the relative allelic
peak heights, in several instances we cannot distinguish between
Table 5. Experimental conditions used for the detection of allelic losses and gains
Marker Forward primer (5030)1,2 Reverse primer (5030)1
Fragment-
size
range (bp) Additives3
DNA
polymerase4
No. of
cycles
PCR Ta
4
(1C)
D1S214 N*-CCGAATGACAAGGTGAGACT AATGTTGTTTCCAAAGTGGC 120–142 1M betaine HotStart 40 50
D1S2766 H*-CTCAGCCTAGTGCAGCC GCTTAAACCCATGATTGGTAT 163–195 1M betaine AmpliTaq 40 50
D2S131 N*-TTTACTGCTGAGACAACCCA GTATAGGAGCCACACCCCTG 229–247 1M betaine AmpliTaq 40 50
D2S2182 6F*-GCTCGAAAAATGATTTGATCC GGCTAAGCCTAGATGCTTGA 228–242 1M betaine AmpliTaq 40 50
D2S2291 N*-TGTCAACAGTGGCTAATCATC TTAGAAATATGGCTGCCAGG 233–245 1M betaine AmpliTaq 40 50
D2S139 H*-AGCTCAAAGCAAATGCATGC AAATTGCGAAACTGTGGCTT 175–197 1M betaine HotStart 50 50
D2S206 H*-TTAAAAATTAAGTAGG
CTTTTGGTT
GTCCTCATGTGTTTATGCTGT 123–151 NA AmpliTaq 40 55
D4S1543 H*-TTCCAGCAATAGGGA
TGGAGTC
CGAAAGTAGTTAATATGG
CTTCCGA
144–170 NA AmpliTaq 40 55
D6S275 N*-TAATTTCACATACAGGCCCT AATGAACACGCTCTAAGGAT 207–219 1M betaine AmpliTaq 50 50
D6S457 N*-ATTGGCAATAGTTACGAATTA GGCATTTGTGGAGTGG 197–207 2% glycerol AmpliTaq 10, 10, 25 55, 53, 51
D6S1043 H*-CAAGGATGGGTGGATCAATA TTGTATGAGCCACTTCCCAT 103–143 1M betaine HotStart 40 50
D7S1824 H*-GTTTGATTCAGTCAGTGG TGGGATAGAACAGAATAG 163–199 1M betaine HotStart 40 50
D8S1104 6F*-TCAGCTATGAGAAAAGT
TGAATG
GACCCTTGTTTGTGTACGGT 129–141 1M betaine HotStart 40 50
D9S304 6F*-GTGCACCTCTACACCCAGAC TGTGCCCACACACATCTATC 135–175 1M betaine AmpliTaq 40 50
D9S157 H*-AGCAAGGCAAGCCACATTTC TGGGGATGCCCAGATAACTATATC 133–149 2% glycerol AmpliTaq 10, 10, 25 55, 53, 51
D10S185 H*-TCCTATGCTTTCATTTGCCA CAAGACACACGATGTGCCAG 143–159 1M betaine AmpliTaq 15, 25 55, 53
D10S212 H*-GAAGTAAAGCAAGTTCT
ATCCACG
TCTGTGTACGTTGAAAATCCC 189–201 1M betaine AmpliTaq 40 50
D10S676 6F*-GAGAACAGACCCCCAAATCT ATTTCAGTTTTACTATGTGCATGC 175–199 1M betaine HotStart 40 50
D11S2000 6F*-AGTAGAGAACAAAACAC
TGTGGC
TTTGAAGATCTGTGAAATGTGC 199–235 1M betaine HotStart 50 50
D11S1998 N*-AGCCATCAACTAGCTTTCCC GGGAGGCACCAACAGATG 129–165 1M betaine HotStart 40 50
RBi2 /
D13S153
6F*-AGCATTGTTTCATGTTGGTG CAGCAGTGAAGGTCTAAGCC 212–236 1M betaine AmpliTaq 15, 25 55, 53
D17S786 H*-TACAGGGATAGGTAGCCGAG GGATTTGGGCTCTTTTGTAA 135–157 1M betaine AmpliTaq 40 50
D17S1322 6F*-CTAGCCTGGGCAACAAACGA GCAGGAAGCAGGAATGGAAC B144 1M betaine HotStart 50 50
TP53 6F*-GAATCCGGGAGGAGGTTG AACAGCTCCTTTAATGGCAG 140–175 1M betaine HotStart 40 50
D3S1293 6F*-ACTCACAGAGCCTTCACA CATGGAAATAGAACAGGGT 116–144 1M betaine AB AmpliTaq 5, 20, 20 56, 55, 53
D1S2882 6F*-AATGAAAATTGTAGTAC
CTGTTTCG
CTTGCTAAGGATGATAGCCTC 224–237 NA AB AmpliTaq 40 55
NA, not applicable; Ta, annealing temperature.
1Primer sequences obtained from UniSTS.
2Forward primer modified with a 50-fluorescent primer: N*, NED; H*, HEX; 6F*, 6FAM.
3Amount of additives shown corresponds to the final concentration in the reaction.
4AB, AmpliTaq (Applied Biosystems); Hot Start , Qiagen Hot Start Taq polymerase (Qiagen).
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loss of an allele and the gain of the contralateral allele. However,
most of the markers used map to chromosomal arms deleted in
melanoma (Thompson et al., 1995; Bastian et al., 1998) and
therefore all allelic changes were designated as LOH. The cutoff to
establish whether LOH had occurred was chosen based upon
microscopic evaluation of the H&E-stained tissues and considered
on a case-to-case basis. As an example, if the tumor sample
contained B20% normal cells, LOH was defined as a 40%
reduction or more in the intensity of one of the two alleles in the
tumor sample (Figure 1) (Orlow et al., 1994).
Normal
MEC-29
MEC-12
MEC-13
170 170 170
190219020190
170 170 170
Tumor 1 Tumor 2
Figure 1. Analysis of allelic gains and losses using fragment-size analysis (FSA). The depicted results correspond to sets of electropherograms obtained
for the tetranucleotide-repeat marker D7S1824 for patients in whom the tumor pairs showed concordant allelic loss (case no. 29, loss of the long allele); loss in
one of the tumors only (case no. 12); and discordant losses (case no. 13, loss of the long allele in tumor 1 versus loss of the long allele in tumor 2).
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Quality control
Careful labeling of study samples and 96-well plates was
monitored throughout all procedures. To avoid contamination,
DNA extraction and pre-PCR procedures including scraping of cells
from the paraffin-embedded tissue were conducted in areas free of
PCR products and with dedicated instrumentation, including
aerosol-resistant pipette tips and disposable plastic ware.
Pipettes were wiped with ethanol and exposed together with
plastic ware to UV for 15 minutes before each use. Samples that
failed to amplify were repeated at least twice. All results
were interpreted at least twice by two laboratory members (D.V.T.
and I.O.)
Statistical analysis
The patterns of mutational events in the two tumors were compared
using a statistical test designed for this specific purpose (Begg et al.,
2007). The test involves counting the total number of concordant
mutations that occur on the same parental allele and benchmarking
this total against a reference distribution that is based on the
assumption that mutations on the two tumors occurred randomly.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Bushra Zaidi for her assistance with the hematoxylin–eosin staining,
Juan Li for her help with the GeneMapper software during the evaluation of
fragment sizes, and Stacey Yang for her assistance in locating tissue blocks
and original pathology reports for multiple primary melanomas. This study
was supported by the National Cancer Institute Awards CA125829,
CA124504, and CA020449-29, the Melanoma Foundation of the University
of Sydney, the Cancer Institute New South Wales, the Australian National
Health and Medical Research Council, and the Memorial Sloan-Kettering
Cancer Center Cancer Education Program.
REFERENCES
Abernethy JL, Soyer HP, Kerl H, Jorizzo JL, White WL (1994) Epidermotropic
metastatic malignant melanoma simulating melanoma in situ.
A report of 10 examples from two patients. Am J Surg Pathol 18:
1140–49
Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D (1998) Chromosomal
gains and losses in primary cutaneous melanomas detected by
comparative genomic hybridization. Cancer Res 58:2170–5
Bastian BC, LeBoit PE, Pinkel D (2000) Mutations and copy number increase
of HRAS in Spitz nevi with distinctive histopathological features. Am J
Pathol 57:967–72
Bastian BC, Olshen AB, LeBoit PE, Pinkel D (2003) Classifying melanocytic
tumors based on DNA copy number changes. Am J Pathol 163:
1765–70
Bastian BC, Wesselmann U, Pinkel D, Leboit PE (1999) Molecular cytogenetic
analysis of Spitz nevi shows clear differences to melanoma. J Invest
Dermatol 113:1065–9
Bedi GC, Westra WH, Gabrielson E, Koch W, Sidransky D (1996) Multiple
head and neck tumors: evidence for a common clonal origin. Cancer Res
56:2484–7
Begg CB (2001) The search for cancer risk factors: when can we stop looking?
Am J Public Health 91:360–4
Begg CB, Berwick M (1997) A note on the estimation of relative risks of rare
genetic susceptibility markers. Cancer Epidemiol Biomarkers Prev
6:99–103
Begg CB, Eng K, Hummer AJ (2007) Statistical tests for clonality. Biometrics
63:522–30
Begg CB, Hummer AJ, Mujumdar U, Armstrong BK, Kricker A, Marrett LD
et al. (2006) A design for cancer case–control studies using only incident
cases: experience with the GEM study of melanoma. Int J Epidemiol
35:756–64
Bengoechea-Beeby MP, Velasco-Ose´s A, Mourin˜o Ferna´ndez F,
Reguilo´n-Rivero MC, Remo´n-Garijo L, Casado-Pe´rez C (1993) Epider-
motropic metastatic melanoma. Are the current histologic criteria
adequate to differentiate primary from metastatic melanoma? Cancer
72:1909–13
Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD et al.
(2006) The prevalence of CDKN2A germline mutations and relative risk
for cutaneous malignant melanoma: an international population-based
study. Cancer Epidemiol Biomarkers Prev 15:1520–5
Cawkwell L, Lewis FA, Quirke P (1994) Frequency of allele loss of DCC,
p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed
by fluorescent multiplex polymerase chain reaction. Br J Cancer
70:813–8
Chunder N, Roy A, Roychoudhury S, Panda CK (2004) Molecular study of
clonality in multifocal and bilateral breast tumors. Pathol Res Pract
200:735–41
Concannon P, Haile RW, Borresen-Dale A-L, Rosenstein BS, Gatti RA,
Teraoka SN et al. (2008) Variants in the ATM gene associated with a
reduced risk of contralateral breast cancer. Cancer Res 68:6486–91
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al.
(2005) Distinct sets of genetic alterations in melanoma. N Engl J Med
353:2135–47
Dacic S, Ionescu DN, Finkelstein S, Yousem SA (2005) Patterns of allelic loss of
synchronous adenocarcinomas of the lung. Am J Surg Pathol 29:897–902
Geurts TW, Nederlof PM, van den Brekel MW, van’t Veer LJ, de Jong D, Hart
AA et al. (2005) Pulmonary squamous cell carcinoma following head
and neck squamous cell carcinoma: metastasis or second primary? Clin
Cancer Res 11:6608–14
Goldstein NS, Vicini FA, Hunter S, Odish E, Forbes S, Kestin LL (2005a)
Molecular clonality relationships in initial carcinomas, ipsilateral breast
failures, and distant metastases in patients treated with breast-conserving
therapy: evidence suggesting that some distant metastases are derived
from ipsilateral breast failures and that metastases can metastasize. Am J
Clin Pathol 124:49–57
Goldstein NS, Vicini FA, Hunter S, Odish E, Forbes S, Kraus D et al. (2005b)
Molecular clonality determination of ipsilateral recurrence of invasive
breast carcinomas after breast-conserving therapy: comparison with
clinical and biologic factors. Am J Clin Pathol 123:679–89
Guerriere-Kovach PM, Hunt EL, Patterson JW, Glembocki DJ, English JC III,
Wick MR (2004) Primary melanoma of the skin and cutaneous
melanomatous metastases: comparative histologic features and immu-
nophenotypes. Am J Clin Pathol 122:70–7
Ha PK, Califano JA (2003) The molecular biology of mucosal field
cancerization of the head and neck. Crit Rev Oral Biol Med 14:363–9
Hafner C, Knuechel R, Stoehr R, Hartmann A (2002) Clonality of multifocal
urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer
101:1–6
Heenan PJ, Clay CD (1991) Epidermotropic metastatic melanoma simulating
multiple primary melanomas. Am J Dermatopathol 13:396–402
Herbst RA, Mommert S, Casper U, Podewski EK, Kiehl P, Kapp A et al. (2000)
11q23 allelic loss is associated with regional lymph node metastasis in
melanoma. Clin Cancer Res 6:3222–7
Hiroshima K, Toyozaki T, Kohno H, Ohwada H, Fujisawa T (1998)
Synchronous and metachronous lung carcinomas: molecular evidence
for multicentricity. Pathol Int 48:869–76
Holst VA, Finkelstein S, Yousem SA (1998) Bronchioloalveolar adenocarci-
noma of lung: monoclonal origin for multifocal disease. Am J Surg Pathol
22:1343–50
Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J (2001) Molecular
analysis of synchronous and metachronous tumors of the lung: impact on
management and prognosis. Ann Diagn Pathol 5:321–9
Imyanitov EN, Suspitsin EN, Grigoriev MY, Togo AV, Kuligina ESh,
Belogubova EV et al. (2002) Concordance of allelic imbalance profiles
www.jidonline.org 1981
I Orlow et al.
Molecular Profiling of Melanomas
in synchronous and metachronous bilateral breast carcinomas. Int J
Cancer 100:557–64
Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S
et al. (2001) Contralateral breast cancer: molecular differentiation
between metastasis and second primary cancer. Breast Cancer Res Treat
67:1–8
Kanetsky PA, Rebbeck TR, Hummer AJ, Panossian S, Armstrong BK, Kricker A
et al. (2006) Population-based study of natural variation in the
melanocortin-1 receptor gene and melanoma. Cancer Res 66:9330–7
Katona TM, Jones TD, Wang M, Eble JN, Billings SD, Cheng L (2007)
Genetically heterogeneous and clonally unrelated metastases may arise
in patients with cutaneous melanoma. Am J Surg Pathol 31:1029–37
Kollias J, Man S, Marafie M, Carpenter K, Pinder S, Ellis IO et al. (2000) Loss of
heterozygosity in bilateral breast cancer. Breast Cancer Res Treat
64:241–51
Lau DH, Yang B, Hu R, Benfield JR (1997) Clonal origin of multiple lung
cancers: K-ras and p53 mutations determined by nonradioisotopic single-
strand conformation polymorphism analysis. Diagn Mol Pathol 6:179–84
Leong PP, Rezai B, Koch WM, Reed A, Eisele D, Lee DJ et al. (1998)
Distinguishing second primary tumors from lung metastases in patients
with head and neck squamous cell carcinoma. J Natl Cancer Inst
90:972–7
Massi D, Sardi I, Urso C, Franchi A, Borgognoni L, Salvadori A et al. (2002)
Microsatellite analysis in cutaneous malignant melanoma. Melanoma
Res 12:577–84
Matsuzoe D, Hideshima T, Ohshima K, Kawahara K, Shirakusa T, Kimura A
(1999) Discrimination of double primary lung cancer from intrapulmon-
ary metastasis by p53 gene mutation. Br J Cancer 79:1549–52
Millikan RC, Hummer A, Begg C, Player J, Rene´ de Cotret A, Winkel S et al.
(2006) Polymorphisms in nucleotide excision repair genes and risk of
multiple primary melanoma: the genes environment and melanoma
study. Carcinogenesis 27:610–8
Murase T, Takino H, Shimizu S, Inagaki H, Tateyama H, Takahashi E et al.
(2003) Clonality analysis of different histological components in
combined small cell and non-small cell carcinoma of the lung. Hum
Pathol 34:1178–84
Nakayama T, Taback B, Turner R, Morton DL, Hoon DS (2001) Molecular
clonality of in-transit melanoma metastasis. Am J Pathol 158:1371–8
Neugut AI, Meadows AT, Robinson E (1999) Introduction. In: Multiple
Primary Cancers, (Neugut AI, Meadows AT, Robinson E, eds). 1st ed.
Philadelphia: Lippincott Williams and Wilkins, 3–11
Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter VE, Cordon-Cardo C
(1994) Chromosome 9 allelic losses and microsatellite alterations in
human bladder tumors. Cancer Res 54:2848–51
Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA et al. (2007)
CDKN2A Germline mutations in individuals with cutaneous malignant
melanoma. J Invest Dermatol 127:1234–43
Pollock PM, Weeraratna A, Trent JM (2003) Genetics and Molecular
Staging. In: Cutaneous Melanoma. (Balch CM, Houghton AN, Sober
AJ, Soong S-j, eds). 4th ed Missouri: Quality Medical Publishing Inc.,
687–712
Regitnig P, Ploner F, Maderbacher M, Lax SF (2004) Bilateral carcinomas of
the breast with local recurrence: analysis of genetic relationship of the
tumors. Mod Pathol 17:597–602
Schlechter BL, Yang Q, Larson PS, Golubeva A, Blanchard RA, de las Morenas
A et al. (2004) Quantitative DNA fingerprinting may distinguish new
primary breast cancer from disease recurrence. J Clin Oncol 22:1830–8
Scholes AG, Woolgar JA, Boyle MA, Brown JS, Vaughan ED, Hart CA et al.
(1998) Synchronous oral carcinomas: independent or common clonal
origin? Cancer Res 58:2003–6
Shimizu S, Yatabe Y, Koshikawa T, Haruki N, Hatooka S, Shinoda M et al.
(2000) High frequency of clonally related tumors in cases of multiple
synchronous lung cancers as revealed by molecular diagnosis. Clin
Cancer Res 6:3994–9
Shin SW, Breathnach OS, Linnoila RI, Williams J, Gillespie JW, Kelley MJ
et al. (2001) Genetic changes in contralateral bronchioloalveolar
carcinomas of the lung. Oncology 60:81–7
Shirasaki F, Takata M, Hatta N, Takehara K (2001) Loss of expression of the
metastasis suppressor gene KiSS1 during melanoma progression and its
association with LOH of chromosome 6q16.3–q23. Cancer Res
61:7422–5
Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral
stratified squamous epithelium; clinical implications of multicentric
origin. Cancer 6:963–8
Sozzi G, Miozzo M, Pastorino U, Pilotti S, Donghi R, Giarola M et al. (1995)
Genetic evidence for an independent origin of multiple preneoplastic
and neoplastic lung lesions. Cancer Res 55:135–40
Stenmark-Askmalm M, Gentile M, Wingren S, Stahl O, South-East Sweden
Breast Cancer Group (2001) Protein accumulation and gene mutation of
p53 in bilateral breast cancer. Acta Oncol 40:56–62
Swetter SM, Ecker PM, Johnson DL, Harvell JD (2004) Primary
dermal melanoma: a distinct subtype of melanoma. Arch Dermatol
140:99–103
Thompson FH, Emerson J, Olson S, Weinstein R, Leavitt SA, Leong SP et al.
(1995) Cytogenetics of 158 patients with regional or disseminated
melanoma. Subset analysis of near-diploid and simple karyotypes.
Cancer Genet Cytogenet 83:93–104
Tse GM, Kung FY, Chan AB, Law BK, Chang AR, Lo KW (2003) Clonal
analysis of bilateral mammary carcinomas by clinical evaluation and
partial allelotyping. Am J Clin Pathol 120:168–74
Uribe P, Wistuba II, Solar A, Balestrini C, Perez-Cotapos ML, Gonzalez S
(2005) Comparative analysis of loss of heterozygosity and microsatellite
instability in adult and pediatric melanoma. Am J Dermatopathol
27:279–85
van Rens MT, Eijken EJ, Elbers JR, Lammers JW, Tilanus MG, Slootweg PJ
(2002) p53 mutation analysis for definite diagnosis of multiple primary
lung carcinoma. Cancer 94:188–96
Walker GJ, Indsto JO, Sood R, Faruque MU, Hu P, Pollock PM et al. (2004)
Deletion mapping suggests that the 1p22 melanoma susceptibility gene
is a tumor suppressor localized to a 9-Mb interval. Genes Chromosomes
Cancer 41:56–64
White WL, Hitchcock MG (1998) Dying dogma: the pathological diagnosis of
epidermotropic metastatic malignant melanoma. Semin Diagn Pathol
15:176–88
Worsham MJ, Wolman SR, Carey TE, Zarbo RJ, Benninger MS, Van Dyke DL
(1995) Common clonal origin of synchronous primary head and neck
squamous cell carcinomas: analysis by tumor karyotypes and fluores-
cence in situ hybridization. Hum Pathol 26:251–61
1982 Journal of Investigative Dermatology (2009), Volume 129
I Orlow et al.
Molecular Profiling of Melanomas
